EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern Oncology

Keren Rouvinov iD, Rashad Naamneh iD, Alexander Yakobson, Wenad Najjar iD, Mahmoud Abu Amna iD, Arina Soklakova, Ez El Din Abu Zeid, Ronen Brenner, Mohnnad Asla, Fahmi Abu Ghalion iD, Ali Abu Juma'a, Amichay Meirovitz und 1 weitere

Diagnostics · 09.02.2026 · 16 (4) · 523

DOI: 10.3390/diagnostics16040523 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 09.02.2026. Verfasst von Keren Rouvinov und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer-Sheva 84105, Israel. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Liquid biopsy, particularly through the analysis of circulating tumor DNA (ctDNA), represents a significant advancement in oncology. Unlike traditional tissue biopsies, ctDNA offers a minimally invasive, real-time approach to cancer management. It has demonstrated considerable potential in early cancer detection, monitoring of therapeutic responses, and assessing minimal residual disease (MRD) to predict recurrence. By enabling comprehensive molecular profiling through a simple blood test, ctDNA supports the core principles of precision oncology, facilitating more personalized and adaptive treatment strategies.

Methods

In the following article we describe the recent developments focused on refining ctDNA detection assays to improve sensitivity and specificity. Advanced technologies, including next-generation sequencing (NGS) and digital PCR, are commonly employed. The integration of artificial intelligence (AI) and multi-omics approaches—such as combining genomic, epigenomic, and transcriptomic data—has further enhanced the analytical power of ctDNA assays.

Results

Emerging evidence shows that ctDNA-based liquid biopsy enables dynamic, real-time tracking of tumor evolution and therapeutic resistance. Clinical studies have demonstrated its efficacy in detecting early-stage cancers, guiding treatment selection, and predicting relapse with higher accuracy than some conventional methods. Moreover, AI-enhanced algorithms have improved signal detection, allowing for more precise and earlier identification of actionable mutations and MRD. Conclusions: ctDNA analysis via liquid biopsy is poised to revolutionize cancer care by offering a non-invasive, precise, and adaptive tool for tumor characterization and monitoring. Although obstacles remain—particularly regarding assay sensitivity, standardization, and economic feasibility—ongoing technological innovations and multi-omics integration are rapidly advancing its clinical viability. With continued progress, ctDNA-based liquid biopsy is likely to become a cornerstone of routine oncology practice.

Schlagwörter

Stichwörter der Autor:innen

cancercirculating tumor DNA (ctDNA)liquid biopsyminimal residual disease (MRD)precision oncology

Autor:innen und Institutionen

  • The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer-Sheva 84105, Israel.
  • Goldman Medical School, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
  • Neurosurgery Department, Soroka Medical Center, Beer-Sheva 84105, Israel.
  • Neurosurgery Department, Hadassah Hebrew University Medical Center, Jerusalem 91200, Israel.
  • Department of Oncology, The Emek Medical Centre, Afula 18341, Israel.
  • Medical School for International Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.

ORCID-Profile: Keren Rouvinov, Rashad Naamneh, Wenad Najjar, Mahmoud Abu Amna, Fahmi Abu Ghalion, Walid Shalata

Zitieren

APA

Rouvinov, K., Naamneh, R., Yakobson, A., Najjar, W., Abu Amna, M., Soklakova, A., Abu Zeid, E. E. D., Brenner, R., Asla, M., Ghalion, F. A., Abu Juma'a, A., Meirovitz, A., & Shalata, W. (2026). The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern Oncology. Diagnostics, 16(4), 523. https://doi.org/10.3390/diagnostics16040523

Vancouver

Rouvinov K, Naamneh R, Yakobson A, Najjar W, Abu Amna M, Soklakova A, et al. The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern Oncology. Diagnostics. 2026;16(4):523. doi:10.3390/diagnostics16040523

BibTeX
@article{Rouvinov2026,
  author = {Rouvinov, Keren and Naamneh, Rashad and Yakobson, Alexander and Najjar, Wenad and Abu Amna, Mahmoud and Soklakova, Arina and Abu Zeid, Ez El Din and Brenner, Ronen and Asla, Mohnnad and Ghalion, Fahmi Abu and Abu Juma'a, Ali and Meirovitz, Amichay and Shalata, Walid},
  title = {The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern Oncology},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {4},
  pages = {523},
  doi = {10.3390/diagnostics16040523}
}
Kostenlos starten →